The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study
Open accessAbstract
Introduction We hypothesized that engineering a combined lymph node/melanoma organoid from the same patient would allow tumor, stroma, and immune system to remain viable for personalized immunotherapy screening. Methods Surgically obtained matched melanoma and lymph node biospecimens from the same patient were transferred to the laboratory and washed with saline, antibiotic, and red blood cell lysis buffer. Biospecimens were dissociated, incorporated into an extracellular matrix (ECM)-based hydrogel system, and biofabricated into three dimensional (3D) mixed melanoma/node organoids. Cells were not sorted, so as to preserve tumor heterogeneity, including stroma and immune cell components, resulting in immune-enhanced patient tumor organoids (iPTOs). Organoid sets were screened in parallel with nivolumab, pembrolizumab, ipilimumab, and dabrafenib/trametinib for 72 h. LIVE/DEAD staining and quantitative metabolism assays recorded relative drug efficacy. Histology and immunohistochemistry were used to compare tumor melanoma cells with organoid melanoma cells. Lastly, node-enhanced iPTOs were employed to activate patient-matched peripheral blood T cells for killing of tumor cells in naïve PTOs. Results Ten biospecimen sets obtained from eight stage III and IV melanoma patients were reconstructed as symbiotic immune/tumor organoids between September 2017 and June 2018. Successful establishment of viable organoid sets was 90% (9/10), although organoid yield varied with biospecimen size. Average time from organoid development to initiation of immunotherapy testing was 7 days. In three patients for whom a node was not available, it was substituted with peripheral blood mononuclear cells. iPTO response to immunotherapy was similar to specimen clinical response in 85% (6/7) patients. In an additional pilot study, peripheral T cells were circulated through iPTOs, and subsequently transferred to naïve PTOs from the same patient, resulting in tumor killing, suggesting a possible role of iPTOs in generating adaptive immunity. Conclusion Development of 3D mixed immune-enhanced tumor/node organoids is a feasible platform, allowing individual patient immune system and tumor cells to remain viable for studying of personalized immunotherapy response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · cited 1×
“9 months with ipilimumab monotherapy.(21,22) Despite advances in immunotherapy, currently there is no 100% human experimental model to recapitulate the interaction between host, tumor, and immune system.”
BackgroundSchadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · cited 1×
“9 months with ipilimumab monotherapy.(21,22) Despite advances in immunotherapy, currently there is no 100% human experimental model to recapitulate the interaction between host, tumor, and immune system.”
BackgroundOrganoid modeling of the tumor immune microenvironment
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556
Dijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., Slagter, M., van der Velden, D. L., Kaing, S., Kelderman, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.009 · Cited by 1,135 · cited 1×
“recently generated tumor-reactive T cells by coculturing them with PTOs from 13 mismatch repair (MMR)-deficient colon and 6 non-small-cell lung carcinoma (NSCLC) patients.(23)”
Yan, H. H. N., Siu, H. C., Law, S., Ho, S. L., Yue, S. S. K., Tsui, W. Y., Chan, D., Chan, A. S., Ma, S., Lam, K. O., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.09.016 · Cited by 724 · cited 1×
“These tumor organoids have demonstrated promising results in predicting individual response to chemotherapy for patients with colorectal and gastroesophageal cancer, with 88% positive predictive value and 100% negative predictive value.(1) The mechanisms of action of immunotherapy drugs require an intact immune system…”
BackgroundMulti-tissue interactions in an integrated three-tissue organ-on-a-chip platform
Skardal, A., Murphy, S. V., Devarasetty, M., Mead, I., Kang, H.-W., Seol, Y.-J., Shrike Zhang, Y., Shin, S.-R., Zhao, L., Aleman, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08879-x · Cited by 623 · cited 1×
“As an optional addition, organoids could be integrated into microfluidic devices, as recently described.(9) PTOs were subsequently maintained in DMEM with 10% FBS (Hyclone, Logan, UT), 1% penicillin–streptomycin, and 1% L-glutamine.”
MethodSelf-citationSkardal, A., Devarasetty, M., Kang, H.-W., Mead, I., Bishop, C., Shupe, T., Lee, S. J., Jackson, J., Yoo, J., Soker, S., et al. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.07.030 · Cited by 428
Self-citationSkardal, A., Devarasetty, M., Forsythe, S., Atala, A., & Soker, S. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.25950 · Cited by 230 · cited 1×
“HP, ESI-BIO, Alameda, CA) that has been previously described.(8,18,19) Briefly, a thiolated HA component (Glycosil, ESI-BIO) and a methacrylated collagen component (Advanced BioMatrix, San Diego, CA) were dissolved in sterile water containing 0.”
BackgroundSelf-citationTissue specific synthetic ECM hydrogels for 3-D in vitro maintenance of hepatocyte function
Skardal, A., Smith, L., Bharadwaj, S., Atala, A., Soker, S., & Zhang, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.034 · Cited by 183
Self-citationPleural Effusion Aspirate for Use in 3D Lung Cancer Modeling and Chemotherapy Screening
Mazzocchi, A., Devarasetty, M., Herberg, S., Petty, W. J., Marini, F., Miller, L., Kucera, G., Dukes, D. K., Ruiz, J., Skardal, A., et al. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01356 · Cited by 82
Self-citation
Cited by
Organoid and Spheroid Tumor Models: Techniques and Applications
Gunti, S., Hoke, A. T. K., Vu, K. P., & London, N. R. (2021) · Cancers · doi:10.3390/cancers13040874 · Cited by 479
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
Wensink, G. E., Elias, S. G., Mullenders, J., Koopman, M., Boj, S. F., Kranenburg, O. W., & Roodhart, J. M. L. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00168-1 · Cited by 323
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Polak, R., Zhang, E. T., & Kuo, C. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00706-6 · Cited by 298
Tumor organoids: applications in cancer modeling and potentials in precision medicine
Xu, H., Jiao, D., Liu, A., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01278-4 · Cited by 286
Thorel, L., Perréard, M., Florent, R., Divoux, J., Coffy, S., Vincent, A., Gaggioli, C., Guasch, G., Gidrol, X., Weiswald, L.-B., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01272-5 · Cited by 236
Metadata
- Authors
- Votanopoulos, K. I., Forsythe, S., Sivakumar, H., Mazzocchi, A., Aleman, J., Miller, L., Levine, E., Triozzi, P., & Skardal, A.
- Venue
- Annals of Surgical Oncology
- Published
- 2019-12-19
- Volume
- 27
- Issue
- 6
- Pages
- 1956-1967
- ISSN
- 1068-9265 (ISSN-L)
- 1534-4681
- OpenAlex
- W2995499586
- Cited by
- 177
- References
- 10
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study. https://app.cochat.ai/papers/10.1245/s10434-019-08143-8
- The paper
- Votanopoulos, K. I., Forsythe, S., Sivakumar, H., Mazzocchi, A., Aleman, J., Miller, L., Levine, E., Triozzi, P., & Skardal, A. (2020). Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-019-08143-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.